1-3 of 3
Thomas C. Shea
Close
Sort by
Journal Articles

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma

Clinical Trials & Observations
Timothy J. Voorhees, Beibo Zhao, Jorge Oldan, George Hucks, Amir Khandani, Christopher Dittus, Jennifer Smith, J. Kaitlin Morrison, Catherine J. Cheng, Anastasia Ivanova, Steven Park, Thomas C. Shea, Anne W. Beaven, Gianpietro Dotti, Jonathan Serody, Barbara Savoldo, Natalie Grover
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1255–1263.
https://doi.org/10.1182/bloodadvances.2021005385
Published: 2022
Includes: Supplemental data
Journal Articles

ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma

Clinical Trials & Observations
Steven I. Park, Thomas C. Shea, Oludamilola Olajide, Nishitha M. Reddy, Lihua E. Budde, Nilanjan Ghosh, Allison M. Deal, Jeanne F. Noe, Stephen M. Ansell
Journal: Blood Advances
Blood Adv (2020) 4 (11): 2548–2555.
https://doi.org/10.1182/bloodadvances.2020001871
Published: 2020
Includes: Supplemental data
Journal Articles

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael L. Leblanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel J. Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3132–3135.
https://doi.org/10.1182/bloodadvances.2019000526
Published: 2019